2seventy bio’s (TSVT) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research note released on Wednesday,Weiss Ratings reports.

2seventy bio Stock Performance

NASDAQ:TSVT opened at $2.61 on Wednesday. 2seventy bio has a fifty-two week low of $2.29 and a fifty-two week high of $6.00. The stock’s fifty day moving average is $2.69 and its 200 day moving average is $3.83. The firm has a market capitalization of $134.64 million, a PE ratio of -1.40 and a beta of 1.74.

Hedge Funds Weigh In On 2seventy bio

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Erste Asset Management GmbH bought a new position in shares of 2seventy bio during the 3rd quarter worth $25,000. Northern Trust Corp grew its position in shares of 2seventy bio by 1.4% during the 4th quarter. Northern Trust Corp now owns 408,083 shares of the company’s stock worth $1,200,000 after buying an additional 5,470 shares in the last quarter. Eversept Partners LP grew its position in shares of 2seventy bio by 0.6% during the 4th quarter. Eversept Partners LP now owns 1,003,678 shares of the company’s stock worth $2,951,000 after buying an additional 5,599 shares in the last quarter. American Century Companies Inc. grew its position in shares of 2seventy bio by 6.6% during the 4th quarter. American Century Companies Inc. now owns 93,552 shares of the company’s stock worth $275,000 after buying an additional 5,785 shares in the last quarter. Finally, Intech Investment Management LLC grew its position in shares of 2seventy bio by 41.1% during the 4th quarter. Intech Investment Management LLC now owns 20,688 shares of the company’s stock worth $61,000 after buying an additional 6,030 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.